ID   DM93
AC   CVCL_6629
SY   DM-93; Duke Melanoma 93
DR   BTO; BTO_0002958
DR   GEO; GSM1572811
DR   GEO; GSM1572812
DR   GEO; GSM1572813
DR   GEO; GSM1572814
DR   GEO; GSM1572815
DR   GEO; GSM1572816
DR   Wikidata; Q54831267
RX   PubMed=2404572;
RX   PubMed=2785141;
RX   PubMed=7703289;
RX   PubMed=10752474;
RX   PubMed=14871852;
RX   PubMed=21654344;
CC   From: Duke University Medical Center; Durham; USA.
CC   Characteristics: Pigmented.
CC   HLA typing: A*02:01,33; B*08,49 (PubMed=10752474).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 17
//
RX   PubMed=2404572;
RA   Crowley N.J., Slingluff C.L. Jr., Darrow T.L., Seigler H.F.;
RT   "Generation of human autologous melanoma-specific cytotoxic T-cells
RT   using HLA-A2-matched allogeneic melanomas.";
RL   Cancer Res. 50:492-498(1990).
//
RX   PubMed=2785141; DOI=10.4049/jimmunol.142.9.3329;
RA   Darrow T.L., Slingluff C.L. Jr., Seigler H.F.;
RT   "The role of HLA class I antigens in recognition of melanoma cells by
RT   tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor
RT   antigens.";
RL   J. Immunol. 142:3329-3335(1989).
//
RX   PubMed=7703289; DOI=10.1089/hum.1995.6.1-87;
RA   Fenton R.T., Sznol M., Luster D.G., Taub D.D., Longo D.L.;
RT   "A phase I trial of B7-transfected or parental lethally irradiated
RT   allogeneic melanoma cell lines to induce cell-mediated immunity
RT   against tumor-associated antigen presented by HLA-A2 or HLA-A1 in
RT   patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol
RT   9401.";
RL   Hum. Gene Ther. 6:87-106(1995).
//
RX   PubMed=10752474; DOI=10.1007/s002620050015; PMCID=PMC11037162;
RA   Slingluff C.L. Jr., Colella T.A., Thompson L., Graham D.D.,
RA   Skipper J.C.A., Caldwell J., Brinckerhoff L., Kittlesen D.J.,
RA   Deacon D.H., Oei C., Harthun N.L., Huczko E.L., Hunt D.F.,
RA   Darrow T.L., Engelhard V.H.;
RT   "Melanomas with concordant loss of multiple melanocytic
RT   differentiation proteins: immune escape that may be overcome by
RT   targeting unique or undefined antigens.";
RL   Cancer Immunol. Immunother. 48:661-672(2000).
//
RX   PubMed=14871852; DOI=10.1158/0008-5472.CAN-03-2209;
RA   Hogan K.T., Coppola M.A., Gatlin C.L., Thompson L.W., Shabanowitz J.,
RA   Hunt D.F., Engelhard V.H., Ross M.M., Slingluff C.L. Jr.;
RT   "Identification of novel and widely expressed cancer/testis gene
RT   isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to
RT   melanoma.";
RL   Cancer Res. 64:1157-1163(2004).
//
RX   PubMed=21654344; DOI=10.1097/CMR.0b013e328343a1d6; PMCID=PMC3131461;
RA   Molhoek K.R., Shada A.L., Smolkin M., Chowbina S., Papin J.,
RA   Brautigan D.L., Slingluff C.L. Jr.;
RT   "Comprehensive analysis of receptor tyrosine kinase activation in
RT   human melanomas reveals autocrine signaling through IGF-1R.";
RL   Melanoma Res. 21:274-284(2011).
//